These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33948221)

  • 1. Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS.
    Hersh CM; Kieseier B; de Moor C; Miller DM; Campagnolo D; Williams JR; Fitzgerald KC; Xiong K; McGinley MP; Hyland M; Rudick RA; Ziemssen T; Koulinska I
    Mult Scler J Exp Transl Clin; 2021; 7(2):20552173211004634. PubMed ID: 33948221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab.
    Hersh CM; Pang M; Miller DM; McGinley MP; Hyland M; Ziemssen T; Avila RL
    Neurodegener Dis Manag; 2024; 14(2):21-33. PubMed ID: 38623894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis.
    Glanz BI; Zurawski J; Casady EC; Shamah R; Weiner M; Chitnis T; Weiner HL; Healy BC
    Mult Scler J Exp Transl Clin; 2021; 7(2):20552173211007523. PubMed ID: 34046184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.
    Foley JF; Nair KV; Vollmer T; Stephenson JJ; Niecko T; Agarwal SS; Watson C
    Patient Prefer Adherence; 2017; 11():1035-1048. PubMed ID: 28670113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
    Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
    Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis.
    Glanz BI; Zurawski J; Gonzalez CT; Shamah R; Ratajska A; Chitnis T; Weiner HL; Healy BC
    Mult Scler Relat Disord; 2020 May; 40():101944. PubMed ID: 32007653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating Individual Change With the Quality of Life in Neurological Disorders (Neuro-QoL) Short Forms.
    Kozlowski AJ; Cella D; Nitsch KP; Heinemann AW
    Arch Phys Med Rehabil; 2016 Apr; 97(4):650-654.e8. PubMed ID: 26740062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.
    Kamat SA; Rajagopalan K; Stephenson JJ; Agarwal S
    Patient; 2009 Jun; 2(2):105-12. PubMed ID: 22273086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple Sclerosis.
    Sater RA; Gudesblatt M; Kresa-Reahl K; Brandes DW; Sater P
    Int J MS Care; 2016; 18(4):177-82. PubMed ID: 27551242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
    Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
    CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
    Sundgren M; Piehl F; Wahlin Å; Brismar T
    Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls.
    Alvarez E; Nair KV; Hoyt BD; Seale RA; Sillau S; Miravalle A; Engebretson E; Schurr B; Corboy JR; Vollmer TL; Honce JM
    Mult Scler Relat Disord; 2021 Oct; 55():103170. PubMed ID: 34364034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab for the treatment of relapsing multiple sclerosis.
    Rudick RA; Panzara MA
    Biologics; 2008 Jun; 2(2):189-99. PubMed ID: 19707353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis.
    Zurawski J; Glanz BI; Healy BC; Tauhid S; Khalid F; Chitnis T; Weiner HL; Bakshi R
    J Neurol Sci; 2019 Aug; 403():38-43. PubMed ID: 31207364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.
    Svenningsson A; Falk E; Celius EG; Fuchs S; Schreiber K; Berkö S; Sun J; Penner IK;
    PLoS One; 2013; 8(3):e58643. PubMed ID: 23555589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. People with multiple sclerosis report significantly worse symptoms and health related quality of life than the US general population as measured by PROMIS and NeuroQoL outcome measures.
    Amtmann D; Bamer AM; Kim J; Chung H; Salem R
    Disabil Health J; 2018 Jan; 11(1):99-107. PubMed ID: 28442320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.